"I think that really establishes this vaccine is out there with the other existing vaccines as extraordinary effective," said Dr. Annie Luetkemeyer, UCSF Professor of Medicine & Infectious Diseases and HIV.
UCSF's Dr. Annie Luetkemeyer and Dr. Susan Buchbinder with the San Francisco Department of Public Health, were both involved in the three Bay Area AstraZeneca trials. This is the part that excited Dr. Buchbinder, "100% is against severe disease hospitalization and deaths. So that's very good news."
RELATED: AstraZeneca, Pfizer, Moderna, Johnson & Johnson: Breaking down the differences between coronavirus vaccines
The safety efficacy analysis of this trial was based on over 32,000 participants in the U.S, Peru and Chile.
"The study has been monitored by data safety monitoring board or DSMB very closely. And it's the same DSMB that is monitoring many of the other studies. Thus far, there have been no concerns about safety," said Dr. Luetkemeyer.
According to Dr. Luetkemeyer, 20% of people who were enrolled in the trial were over the age of 65 and added " It's 80% effective in preventing symptomatic disease in people over the age of 65."
Multiple European countries stopped the use of AstraZeneca after 18 out of 2 million people reported blood clots in the brain in the U.K.
RELATED: Spain, Germany, France, Italy pause AstraZeneca vaccine rollout over small number of blood clot concerns
"It was an extremely rare event," said Dr. Buchbinder and added, "They found that there were actually more in the placebo arm than there were in the vaccine arm. So there was no excess rate of blood clotting in the vaccine trial itself."
Dr. Buchbinder highlighted that the AstraZeneca vaccine trains the body, so if you are later exposed to COVID "you will recognize it and clear it out of the system effectively."
Luz Pena: "Is there anything particularly from the AstraZeneca vaccine that might be causing these blood clots?"
Dr. Luetkemeyer: "If you just look at millions of people you will find that people will get blood clots so there is not something specific that I think is different about AstraZeneca. There are some small differences between all these vaccines some have to do with the type of envelope that it uses and the DNA information is delivered."
Having trouble loading the tracker above? Click here to open it in a new window.
VACCINE TRACKER: How California is doing, when you can get a coronavirus vaccine
Researchers in Norway and Germany found that the AstraZeneca vaccine could potentially trigger an autoimmune reaction leading to these clots.
"I think that is a hypothesis that those researches have, and we do know that coronavirus in general can be associated with a robust immune response including some autoimmune response. I really think it's too soon to say with certainty," said Dr. Luetkemeyer.
Both doctors agree that based on the U.S data, this vaccine is effective no blood clots have been reported in the U.S trials.
RELATED STORIES & VIDEOS:
- Map shows which counties can, can't reopen under reopening tiers
- Cheat sheet: What you can and can't do after being fully vaccinated
- How to register for a COVID-19 vaccine in every Bay Area county
- Map shows everywhere you can get a COVID-19 test in the Bay Area
- Interactive map shows what's closed and what's reopening in the San Francisco Bay Area
- Data tracker: Coronavirus cases, deaths, hospitalizations in every Bay Area county
- Third stimulus check calculator: See how much you could get
- COVID-19 Diaries: Personal stories of Bay Area residents during pandemic
- Get the latest updates on California EDD, stimulus checks, unemployment benefits
- Coronavirus origin: Where did COVID-19 come from?
- What is a COVID-19 genetic, antigen and antibody test?
- What does COVID-19 do to your body and why does it spread so easily?
- Coronavirus Timeline: Tracking major moments of COVID-19 pandemic in San Francisco Bay Area
- Coronavirus Doctor's Note: Dr. Alok Patel gives his insight into COVID-19 pandemic